Commentary - (2024) Volume 10, Issue 2
Received: 20-Mar-2024, Manuscript No. aso-24-136092;
Editor assigned: 22-Mar-2024, Pre QC No. P-136092;
Reviewed: 05-Apr-2024, QC No. Q-136092;
Revised: 10-Apr-2024, Manuscript No. R-136092;
Published:
17-Apr-2024
, DOI: 10.37421/2471-2671.2024.10.104
Citation: Lia, Geviren. “Genomic Insights into Mixed
Adenosquamous Cell Carcinoma of the Prostate and its Liver Metastasis.” Arch
Surg Oncol 10 (2024): 104.
Copyright: © 2024 Lia G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Mixed Adenosquamous Carcinoma (ASC) of the prostate is an exceedingly rare and aggressive variant of prostate cancer, characterized by the presence of both adenocarcinoma and squamous cell carcinoma components. The genomic landscape of this malignancy and its propensity for metastasis, particularly to the liver, remains poorly understood. This review explores the current understanding of the genomic features of mixed ASC of the prostate and its liver metastases, highlighting key mutations, pathways, and potential therapeutic targets. Prostate cancer typically originates as adenocarcinoma, with common mutations in genes such as PTEN, TP53, RB1, SPOP and AR (Androgen Rceptor). In contrast, squamous differentiation in ASC introduces a distinct and complex genetic profile [1].
Loss-of-function mutations in TP53 and RB1 are common in high-grade prostate cancers, including ASCs. These mutations lead to impaired cell cycle regulation and apoptosis, contributing to aggressive tumor behavior. Deletion or inactivation of PTEN results in hyperactivation of the PI3K/AKT/mTOR pathway, promoting cell survival and growth. Alterations in the androgen receptor pathway, including amplifications and mutations, can drive the progression of prostate cancer, even in castration-resistant settings. Aberrations in the NOTCH signaling pathway, particularly NOTCH1 mutations, have been implicated in squamous cell carcinoma differentiation. NOTCH1 mutations may disrupt normal cell differentiation and promote a squamous phenotype. SOX2, a transcription factor critical for stem cell maintenance and differentiation, is often amplified in squamous cell carcinomas and may play a role in the squamous component of ASCs. ASCs exhibit significant genomic instability, with high levels of chromosomal aberrations and structural variations. This instability may underpin the aggressive nature and treatment resistance observed in these tumors [2].
The metastatic spread of mixed ASC to the liver involves complex interactions between tumor cells and the microenvironment, mediated by specific genomic alterations and signaling pathways. EMT is a critical process in cancer metastasis, allowing epithelial cells to acquire mesenchymal, migratory, and invasive properties. Key regulators of EMT, such as TWIST1, SNAIL, and ZEB1, are often upregulated in metastatic ASCs. Differential expression of miRNAs, such as miR-200 family members, can regulate EMT and metastasis. Loss of miR-200 expression has been linked to increased EMT and metastatic potential. The HGF/c-MET signaling axis is crucial for liver metastasis. Overexpression or activation of c-MET, often driven by gene amplification or mutations, promotes tumor cell proliferation, survival, and migration. Inhibition of c-MET has shown promise in preclinical models, suggesting potential therapeutic avenues for targeting liver metastases in ASC [3].
CRISPR-Cas9, a groundbreaking gene-editing technology, has revolutionized molecular biology by allowing precise, directed changes to the DNA of living organisms. This technology is pivotal for precision medicine as it enables researchers to correct genetic defects at their source. Diseases such as cystic fibrosis, caused by mutations in the CFTR gene, are prime candidates for CRISPR-based therapies. By correcting the faulty gene, CRISPR has the potential to cure genetic diseases, not just treat their symptoms [4].
Tumor cells exploit various mechanisms to evade immune surveillance, including the upregulation of immune checkpoint molecules such as PD-L1. Immune checkpoint inhibitors have shown efficacy in some subsets of metastatic prostate cancers, providing a rationale for their exploration in ASC. The genomic complexity and heterogeneity of mixed ASC pose significant challenges for treatment. Standard therapies for prostate adenocarcinoma, such as androgen deprivation therapy (ADT) and chemotherapy, are often less effective against the squamous component. Anti-PD-1/PD-L1 therapies have shown promise in prostate cancer with high mutational burden or mismatch repair deficiency. Their efficacy in ASC, particularly in the context of liver metastasis, warrants further investigation. Combining targeted therapies with immunotherapy or conventional treatments may enhance therapeutic efficacy and overcome resistance mechanisms. For instance, combining PI3K/AKT/mTOR inhibitors with immune checkpoint inhibitors could provide synergistic effects [5].
Mixed adenosquamous carcinoma of the prostate represents a highly aggressive and genomically complex malignancy with a distinct propensity for liver metastasis. Understanding the genomic underpinnings of this disease is crucial for developing effective therapeutic strategies. Key genomic alterations, such as mutations in TP53, RB1, NOTCH1, and amplification of SOX2, along with pathways involved in EMT and immune evasion, offer potential targets for novel treatments. However, the rarity and heterogeneity of ASC pose significant challenges for clinical management, necessitating continued research and personalized therapeutic approaches.
None.
None.
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Archives of Surgical Oncology received 37 citations as per Google Scholar report
